Cost-effectiveness of Lecanemab for the Treatment of Early Alzheimer’s Disease: A Canadian Societal Perspective
Burn et al
Cost-effectiveness of Lecanemab for the Treatment of Early Alzheimer’s Disease: A Canadian Societal Perspective
